Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 7, 2006, Pages 2022-2025

  Cases Thomas, Manuel J ^a   Masters, John J ^a   Walter, Magnus W ^a   Campbell, Gordon ^a   Haughton, Louise ^a   Gallagher, Peter T ^a   Dobson, David R ^a   Mancuso, Vincent ^b   Bonnier, Benjamin ^b   Giard, Thierry ^b   Defrance, Thierry ^b   Vanmarsenille, Michel ^b   Ledgard, Andrew ^a   White, Craig ^a   Ouwerkerk Mahadevan, Sivi ^b   Brunelle, Francoise J ^b   Dezutter, Nancy A ^b   Herbots, Camy A ^b   Lienard, Joel Y ^b   Findlay, Jeremy ^a   Hayhurst, Lorna ^a   Boot, John ^a   Thompson, Linda K ^a   Hemrick Luecke, Susan ^a   more..

^a ELI LILLY AND COMPANY   (United States)

^b Eli Lilly Benelux   (Belgium)

Author keywords

MMT; ADHD; Atomoxetine; Attention deficit hyperactivity disorder; Depression; Dopamine; Inhibitor; Metariminol; Morpholine; Norepinephrine; Reuptake; Selective norepinephrine reuptake inhibitor; Serotonin; Tertiary alcohol

Indexed keywords

ALCOHOL DERIVATIVE; BENZENE DERIVATIVE; DOPAMINE; MORPHOLINE DERIVATIVE; NORADRENALIN; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; PROTEIN INHIBITOR; REAGENT; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; DRUG POTENCY; GRIGNARD REACTION; NONHUMAN; RAT; STEREOCHEMISTRY;

ALCOHOLS; CRYSTALLOGRAPHY, X-RAY; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MORPHOLINES; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS;

ANIMALIA;

EID: 33144462082     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.12.061     Document Type: Article

References (22)

1. F.P. Bymaster, R.K. McNamara, and P.V. Tran Expert Opin. Investig. Drugs 12 2003 531
2. M. Hajós, J.C. Fleishaker, J.K. Filipiak-Reisner, M.T. Brown, and E.H.F. Wong CNS Drug Rev. 10 2004 23
3. L.S. Eiland, and A.L. Guest Ann. Pharmacother. 38 2004 86
4. F.P. Bymaster, E.E. Beedle, J. Findlay, P.T. Gallagher, J.H. Krushinski, S. Mitchell, D.W. Robertson, D.C. Thompson, L. Wallace, and D.T. Wong Bioorg. Med. Chem. Lett. 13 2003 4477
5. F.P. Bymaster, T.C. Lee, M.P. Knadler, M.J. Detke, and S. Iyengar Curr. Pharm. Des. 11 2005 1475
6. J. Boot, M. Cases, B.P. Clark, J. Findlay, P.T. Gallagher, L. Hayhurst, T. Man, C. Montalbetti, R.E. Rathmell, H. Rudyk, M.W. Walter, M. Whatton, and V. Wood Bioorg. Med. Chem. Lett. 15 2005 699
7. C.D. Beadle, J. Boot, N.P. Camp, N. Dezutter, J. Findlay, L. Hayhurst, J.J. Masters, R. Penariol, and M.W. Walter Bioorg. Med. Chem. Lett. 15 2005 4432
8. Cases, M.; Campbell, G.; Haughton, L.; Masters, J. J.; Walter, M. W.; Gallagher, P. T.; Dobson, D. R.; Finn, T.; Bonnier, B.; White, C.; Findlay, J. D.; Hayhurst, L.; Kluge, A. H.; Mahadevan, S.; Brunelle, F. J.; Delatour, C. L.; Lavis, A. A.; Dezutter, N. A.; Vervaeke, V. N.; Lienard, J. Y.; Boot, J. R. Abstracts of Papers, 229th ACS National Meeting, San Diego, CA, United States, March 13-17, 2005; MEDI-058.
9. Cases-Thomas, M. J.; Haughton, H. L.; Lamas-Peteira, C.; Ouwerkerk-Mahadevan, S.; Masters, J. J.; Simmonds, R. G.; Rudyk, H. C. E.; Walter, M.W. WO2004018441.
10. F.D. King, and R.T. Martin Tetrahedron Lett. 32 1991 2281
11. 2 with 0.2% DEMA (diethylmethylamine); temperature: 35°C; outlet pressure: 100 bar; injection: 1 ml (500 mg); detection: UV at 260 nm.
12. 20 +29.7° (MeOH, 11.78 g/l). Other data identical to enantiomer 1.
13. See Ref. 8 for detailed experimental procedures for Grignard addition and deprotection. Enantiomer separation was achieved using the following methods: isomers 1 and 2 chiral HPLC on a Chiralpak AD 10 μm column (supplied from Chiral technologies, Illkirch, France) with 85% heptane: 15% ethanol (0.2% DMEA) as eluent using a flow rate of 12 ml/min and UV detection at 260 nm. Isomers 3 and 4 chiral HPLC on a Chiralpak AD 10 μm column (supplied from Chiral technologies, Illkirch, France) with 85% heptane: 15% ethanol (0.2% DMEA) as eluent using a flow rate of 12 ml/min and UV detection at 260 nm.
14. CCDC 291659 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.ac.uk/ data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.
15. NET assay: J. Gobel, D.L. Saussy, and A.S. Goetz J. Pharmacol. Toxicol. Methods 42 1999 237
16. SERT/DAT assay: S. Ramamoorthy, E. Giovanetti, Y. Qian, and R.D. Blakely J. Biol. Chem. 273 1998 2458
17. F.P. Bymaster, J.S. Katner, D.L. Nelson, S.K. Hemrick-Luecke, P.G. Threlkeld, J.H. Heiligenstein, S.M. Morin, D.R. Gehlert, and K.W. Perry Neuropsychopharmacology 27 2002 699
18. Remaining parent compound 16 after 15 min incubation in liver microsomes (1 μmol/l, 0.5 mg/ml protein) of different species: Human 98%, Dog 60% and Rat 0%.
19. Compound 15 was shown to be configurationally stable in solution for at least 3 days at 40°C, in water, 0.1 N HCl and in buffer solutions over a pH range of 2-8.
20. R.W. Fuller, and S.K. Hemrick-Luecke Res. Commun. Chem. Pathol. Pharmacol. 41 1983 169
21. P.A. Shore, D. Busfield, and H.S. Alpers J. Pharmacol. Exp. Ther. 146 1964 194
22. Male Sprague-Dawley rats gavaged 1 h prior to 6.25 mg/kg subcutaneous α-MMT. Rats sacrificed 4 h after α-MMT administration (N = 5).